Molecular signature and use thereof for the identification of indolent prostate cancer

US12123058B2 · kind B2 · utility

Assignees

• Sorbonne Universite · FR
• CTRE RECHERCHE PATHOLOGIES PROSTATIQUES · FR
• LIGUE NATIONALE CONTRE LE CANCER · FR
• ASSISTANCE PUBLIQUE—HÔPITAUX DE PARIS (APHP) · FR
• INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE) · FR
• UNIVERSITÉ DE TOURS · FR
• Centre Hospitalier Regional Et Universitaire De Brest · FR

Inventors

• Olivier Cussenot · Paris, FR
• Aurelie Kamoun · Paris, FR
• Aurélien De Reynies · Paris, FR
• Géraldine Cancel-Tassin · Soisy-sur-Seine, FR
• Gaëlle Fromont-Hankard · La Gruaudière, FR

Key dates

• Filing date: Jan 25, 2019
• Grant date: Oct 22, 2024
• Expiry date: Feb 25, 2042

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C12Q2600/158
• WIPO field: Biotechnology
• WIPO sector: Chemistry

Abstract

A method for predicting the risk of prostate cancer recurrence in a subject affected with prostate cancer, including: (a) providing a sample from the subject, (b) determining the TMPRSS/ERG fusion status of the sample, (c) if the sample is positive for TMPRSS/ERG fusion (Fus+), determining a molecular signature of the sample by measuring the expression level of at least 6 prostate cancer markers selected from the ANPEP, AZGP1, CHRNA2, COMP, KHDRBS3 and SFRP4, (d) comparing the molecular signature to a reference signature, and (e) assigning the subject to a risk group based on the correlation of the molecular signature with the reference signature, thereby predicting the risk of cancer recurrence in the subject.